Early Diagnosis of Preeclampsia (Yissum)
- Summary
- Diagnostic for early detection of preeclampsia in blood of pregnant women
Clinical symptoms of preeclampsia usually begin to be manifested from week 20
Studies in healthy and preeclampsic human placentas
Detected protein in human serum from weeks 15-17 – proof of concept for ELISA testsA human-specific splicing variant of VEGF receptor 1 (Flt1) was discovered, producing a soluble receptor (designated sFlt1-14) that is qualitatively different from the previously described soluble receptor (sFlt1), and functioning as a potent VEGF inhibitor. Expression of sFlt1-14 is dramatically elevated in the placenta of women with preeclampsia (PE). Two antibodies to the human-specific isoform of the gene responsible for preeclampsia were produced.Preeclampsia affects both the mother and the unborn baby in 5-8% of all pregnancies and is a leading global cause of maternal and infant illness and death. By conservative estimates, preeclampsia and other hypertensive disorders of pregnancy are responsible for 76,000 deaths each year.
- Technology Application
- Simple blood test to demonstrate presence of condition from 15th week of pregnancy
Enables increased prenatal vigilance before onset of clinical symptoms to protect both fetus and maternal organs
- ID No.
- 6-2006-1698
- Country/Region
- Israel
For more information, please click Here
